Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Nicholas C. Turner, Ben O’Leary et al.|Clinical Cancer Research|2019Cited by 137
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Joline S.J. Lim et al.|Cancer Discovery|2020Cited by 67
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerMaría Teresa Herrera-Abreu, Nicholas C. Turner|Nature Communications|2024Cited by 28